A glucagon secreting alpha-cell
carcinoma of the pancreas.
Drug analysis based on mechanism (alpha-cell
mass decline, kidney protection, insulin sensitizers, Triglyceride lowering, weight loss ?-cell mass increase, ?-cell mass decline, ?-cell protection & ?-cell regeneration).
expansion has been associated with the development of pancreatic neuroendocrine tumors.
Glucogenic syndrome is a dermatosis associated with alpha-cell
tumor of the pancreas.
In addition to th e insulin abnormalities, a relative glucagon excess and a pancreatic alpha-cell
dysfunction have been demonstrated (Unger 1978).
Functional and structural adaptations in the pancreatic alpha-cell
and changes in glucagon signaling during protein malnutrition.
reported the nonbeta islet endocrine cell remodeling in diabetic NOD mice: that study suggested that infiltrating immune cells may restrict alpha-cell
expansion in NOD mouse islet in the diabetic state .
This prompted a CT scan, which revealed a distinct mass that appeared to be a pancreatic alpha-cell
glucagon-secreting tumor, or glucagonoma.